X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2128) 2128
Book Review (757) 757
Publication (120) 120
Book Chapter (8) 8
Conference Proceeding (5) 5
Magazine Article (2) 2
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (1885) 1885
humans (1850) 1850
diabetes mellitus, type 2 - drug therapy (1380) 1380
dipeptidyl-peptidase iv inhibitors - therapeutic use (1087) 1087
male (903) 903
hypoglycemic agents - therapeutic use (848) 848
type 2 diabetes (846) 846
female (766) 766
dipeptidyl-peptidase iv inhibitors - adverse effects (730) 730
endocrinology & metabolism (710) 710
middle aged (657) 657
diabetes (632) 632
hypoglycemic agents - adverse effects (552) 552
aged (531) 531
animals (482) 482
treatment outcome (482) 482
glucagon-like peptide-1 (458) 458
pharmacology & pharmacy (452) 452
sitagliptin (435) 435
diabetes mellitus, type 2 - blood (412) 412
adamantane - analogs & derivatives (387) 387
double-blind (384) 384
adult (380) 380
glucose (375) 375
metformin (365) 365
dipeptidyl-peptidase iv inhibitors - administration & dosage (359) 359
hypoglycemic agents (353) 353
dipeptidyl-peptidase iv inhibitors - pharmacology (347) 347
glycemic control (346) 346
dipeptidyl peptidase-4 inhibitor (343) 343
drug therapy, combination (330) 330
hypoglycemic agents - administration & dosage (318) 318
risk factors (308) 308
blood glucose - drug effects (302) 302
blood glucose - metabolism (296) 296
insulin (279) 279
diabetes mellitus (275) 275
vildagliptin (275) 275
care and treatment (267) 267
dipeptidyl peptidase 4 - metabolism (261) 261
safety (259) 259
analysis (258) 258
metformin - therapeutic use (255) 255
sitagliptin phosphate (253) 253
adamantane - therapeutic use (248) 248
drug therapy (247) 247
type 2 diabetes mellitus (247) 247
type-2 diabetes-mellitus (245) 245
diabetes therapy (238) 238
glycated hemoglobin a - metabolism (235) 235
diabetes mellitus, type 2 - complications (234) 234
double-blind method (233) 233
efficacy (225) 225
dipeptidyl peptidase-4 inhibitors (222) 222
internal medicine (219) 219
beta-cell function (218) 218
hypoglycemic agents - pharmacology (213) 213
medicine, general & internal (212) 212
adamantane - adverse effects (201) 201
dpp-4 inhibitor (201) 201
research (201) 201
improves glycemic control (195) 195
dextrose (192) 192
clinical trials (191) 191
hypoglycemia - chemically induced (187) 187
linagliptin (187) 187
abridged index medicus (178) 178
therapy (177) 177
hypoglycemia (171) 171
glucagon (170) 170
mellitus (169) 169
triazoles - therapeutic use (169) 169
pyrazines - therapeutic use (168) 168
risk (165) 165
sulfonylurea compounds - therapeutic use (161) 161
diabetes mellitus, type 2 - metabolism (160) 160
pyrrolidines - therapeutic use (158) 158
medicine & public health (157) 157
dosage and administration (155) 155
rats (155) 155
peptidase (154) 154
randomized controlled trials as topic (154) 154
dpp-4 inhibitors (153) 153
peptides (153) 153
health aspects (151) 151
nitriles - therapeutic use (151) 151
dipeptidyl-peptidase iv inhibitors - pharmacokinetics (148) 148
hyperglycemia (147) 147
cardiac & cardiovascular systems (146) 146
dipeptidyl-peptidase iv inhibitors (146) 146
mice (145) 145
glp-1 (144) 144
incretins - therapeutic use (143) 143
drug-naive patients (142) 142
pharmacokinetics (140) 140
diabetes mellitus, type 2 - physiopathology (137) 137
time factors (137) 137
saxagliptin (133) 133
mortality (126) 126
glycosylated hemoglobin (124) 124
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2072) 2072
French (17) 17
German (15) 15
Spanish (15) 15
Japanese (7) 7
Hungarian (3) 3
Russian (3) 3
Czech (2) 2
Danish (1) 1
Dutch (1) 1
Italian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Diabetes, Obesity and Metabolism, ISSN 1462-8902, 06/2018, Volume 20, Issue 6, pp. 1542 - 1546
The safety of triple oral therapy with dapagliflozin plus saxagliptin plus metformin versus dual therapy with dapagliflozin or saxagliptin plus metformin was... 
type 2 diabetes | DPP | dapagliflozin | metformin | SGLT | 2 inhibitor | 4 inhibitor | DPP-4 inhibitor | SGLT-2 inhibitor | EVENTS | EFFICACY | DOUBLE-BLIND TRIAL | PLUS METFORMIN | ENDOCRINOLOGY & METABOLISM | TYPE-2 DIABETES-MELLITUS | Benzhydryl Compounds - administration & dosage | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Glycated Hemoglobin A - metabolism | Humans | Middle Aged | Glycated Hemoglobin A - drug effects | Male | Metformin - adverse effects | Benzhydryl Compounds - adverse effects | Hypoglycemic Agents - administration & dosage | Sodium-Glucose Transporter 2 Inhibitors - administration & dosage | Female | Metformin - administration & dosage | Adamantane - administration & dosage | Drug Therapy, Combination | Hypoglycemia - chemically induced | Glucosides - adverse effects | Adamantane - adverse effects | Adamantane - analogs & derivatives | Sodium-Glucose Transporter 2 Inhibitors - adverse effects | Double-Blind Method | Dipeptides - adverse effects | Treatment Outcome | Dipeptidyl-Peptidase IV Inhibitors - administration & dosage | Dipeptides - administration & dosage | Diabetes Mellitus, Type 2 - blood | Glucosides - administration & dosage | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Type 2 diabetes | Urinary tract infections | Hypoglycemic agents | Safety and security measures | Analysis | Diabetes therapy | Diabetes mellitus | Clinical trials | Urinary tract | Safety | Metformin | Hypoglycemia | Diabetes mellitus (non-insulin dependent) | Index Medicus | SGLT‐2 inhibitor | Brief Reports | DPP‐4 inhibitor | Brief Report
Journal Article
PLoS ONE, ISSN 1932-6203, 05/2015, Volume 10, Issue 5, pp. e0124287 - e0124287
Background/Objectives Data on the comparative effectiveness of oral antidiabetics on cardiovascular outcomes in a clinical practice setting are limited. This... 
METAANALYSIS | ORAL ANTIHYPERGLYCEMIC AGENTS | SAFETY | MULTIDISCIPLINARY SCIENCES | PATIENTS PRESCRIBED SITAGLIPTIN | DPP-4 | MELLITUS | BLOOD-PRESSURE | Myocardial Infarction - epidemiology | Metformin - therapeutic use | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Humans | Middle Aged | Male | Metformin - adverse effects | Incidence | Young Adult | Drug Therapy, Combination - adverse effects | Thiazolidinediones - therapeutic use | Cardiovascular Diseases - epidemiology | Adult | Female | Stroke - epidemiology | Retrospective Studies | Heart Failure - epidemiology | Hypoglycemic Agents - therapeutic use | Sulfonylurea Compounds - therapeutic use | Proportional Hazards Models | Treatment Outcome | Cardiovascular System - drug effects | Sulfonylurea Compounds - adverse effects | Thiazolidinediones - adverse effects | Aged | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Cohort Studies | Care and treatment | National health insurance | Analysis | Research | Health aspects | Heart attack | Diabetes therapy | Myocardial infarction | Cerebral infarction | Health insurance | Stroke | Peptidase | Insurance claims | Pioglitazone | Diabetes mellitus | Medical services | Health risks | Population studies | Hazards | Preventive medicine | Patients | Confidence intervals | Prescription drugs | Inhibitors | Ischemia | Sulfonylurea | Infarction | Metformin | Cardiovascular diseases | Heart diseases | Index Medicus
Journal Article
Diabetes Care, ISSN 0149-5992, 2014, Volume 37, Issue 9, pp. 2435 - 2441
Journal Article
Journal Article
International Journal of Clinical Practice, ISSN 1368-5031, 11/2010, Volume 64, Issue 12, pp. 1619 - 1631
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 04/2012, Volume 14, Issue 4, pp. 348 - 357
Aims: To evaluate the efficacy and safety of linagliptin 5 and 10 mg vs. placebo and voglibose in Japanese patients with type 2 diabetes mellitus (T2DM).... 
glucosidase inhibitor | DPP‐4 inhibitor | glycaemic control | incretin therapy | Incretin therapy | α-glucosidase inhibitor | DPP-4 inhibitor | Glycaemic control | CONTROLLED-TRIAL | METFORMIN | DIPEPTIDYL PEPTIDASE-4 INHIBITOR | SULFONYLUREA | EFFICACY | MELLITUS | COMBINATION | a-glucosidase inhibitor | BETA-CELL FUNCTION | PHARMACOKINETICS | ENDOCRINOLOGY & METABOLISM | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Humans | Middle Aged | Male | Purines - administration & dosage | Diabetes Mellitus, Type 2 - epidemiology | Dose-Response Relationship, Drug | Inositol - therapeutic use | Aged, 80 and over | Adult | Female | Quinazolines - administration & dosage | Linagliptin | Purines - adverse effects | Purines - therapeutic use | Hypoglycemic Agents - therapeutic use | Double-Blind Method | Drug Administration Schedule | Japan | Treatment Outcome | Inositol - analogs & derivatives | Dipeptidyl-Peptidase IV Inhibitors - administration & dosage | Blood Glucose - drug effects | Analysis of Variance | Quinazolines - therapeutic use | Quinazolines - adverse effects | Aged | Diabetes Mellitus, Type 2 - drug therapy | Type 2 diabetes | Medical colleges | Medical research | Safety and security measures | Glycosylated hemoglobin | Medicine, Experimental | Hemoglobin | Hypoglycemic agents | Universities and colleges | Diabetes | Diabetes therapy | Index Medicus
Journal Article
Journal Article
Journal of the American Heart Association, ISSN 2047-9980, 02/2013, Volume 2, Issue 1, pp. e003277 - n/a
Journal Article